BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Med-tech outlook 2026
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Monday, March 16, 2026
Home
»
Newsletters
» BioWorld Science
BioWorld Science
July 25, 2005
View Archived Issues
Abzymes --a new drug target for atherosclerosis treatment
Read More
Pradefovir reduces viral load of patients with chronic hepatitis B
Read More
Therapeutic benefits of mometasone furoate spray in nasal polyposis
Read More
SLV-323 demonstrates certain antidepressant-like activity in vivo / News in Context
Read More
Antitumor responses in lung cancer induced by COX-2 inhibition
Read More
Emezine NDA accepted for review
Read More
Oral low-dose interferon alpha to be studied for Behcet's disease
Read More
FDA advisory panel recommends continued availability of Serevent
Read More
Phase IIb trial of cetilistat in obese diabetics completes enrollment
Read More
Cilag to acquire European nesiritide rights from GlaxoSmithKline
Read More
BEYOND study of Betaferon completes enrollment
Read More
Approval of Onyx for treatment of arteriovenous malformations
Read More
Update on the clinical effects of ciclesonide in asthma
Read More
ABT-751 shows promise in the treatment of advanced NSCLC
Read More
RC-1291 enters phase II for cachexia in cancer patients
Read More
Clinical trials evaluate TLK-286 plus chemotherapy as first-line therapy for advanced NSCLC
Read More
RC-8800 for prostate cancer enters clinical testing
Read More
New data on the pharmacokinetics and safety of S-3304 in healthy subjects
Read More
Therapeutic agents for osteoporosis jointly reported by Novartis and Signal researchers
Read More
Motexafin gadolinium under phase I clinical evaluation in NSCLC
Read More
New treatments for cancer covered in recent patents
Read More
Phase III Parkinson's disease study of safinamide completes enrollment
Read More
Recent patents disclose novel agents for treating diabetes
Read More
Epilepsy Foundation of America welcomes use of VNS Therapy
Read More
Evotec and Almirall sign library synthesis agreement
Read More
Enrollment completed in low dose arm of Trinam phase II study
Read More
